{"_links": {"parentPackage": {"href": "/mdr/ct/packages/protocolct-2023-06-30", "title": "Protocol Controlled Terminology Package 54 Effective 2023-06-30", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/protocolct-2023-03-31/codelists/C139020", "title": "CDISC Protocol Entities Clinical Trial Attribute Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/protocolct/codelists/C139020", "title": "Version-agnostic anchor resource for codelist C139020", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/protocolct-2023-06-30/codelists/C139020", "title": "CDISC Protocol Entities Clinical Trial Attribute Terminology", "type": "Code List"}}, "conceptId": "C139020", "definition": "A terminology value set relevant to the attributes of the clinical trial entity.", "name": "Clinical Trial Attribute Terminology", "preferredTerm": "CDISC Protocol Entities Clinical Trial Attribute Terminology", "submissionValue": "Clinical Trial Attribute Terminology", "synonyms": ["Clinical Trial Attribute Terminology"], "terms": [{"conceptId": "C139170", "definition": "The country in which participants are located when enrolling in a trial or study.", "preferredTerm": "Country of Recruitment", "submissionValue": "Country of Recruitment"}, {"conceptId": "C139171", "definition": "Date or date and time of first subject enrollment into a study, as verifiable by a convention that is consistent with authoritative regulatory criteria. [Modified from ICH E3] (CDISC Glossary)", "preferredTerm": "Date of First Enrollment into Study", "submissionValue": "Date of First Enrollment"}, {"conceptId": "C25370", "definition": "List of characteristics in a protocol, any one of which may exclude a potential subject from participation in a study. (CDISC glossary)", "preferredTerm": "Exclusion Criteria", "submissionValue": "Exclusion Criteria"}, {"conceptId": "C25532", "definition": "The criteria in a protocol that prospective subjects must meet to be eligible for participation in a study. NOTE: Exclusion and inclusion criteria define the study population. See also exclusion criteria. (CDISC glossary)", "preferredTerm": "Inclusion Criteria", "submissionValue": "Inclusion Criteria"}, {"conceptId": "C127796", "definition": "The approximate period of time over which the clinical trial is expected to occur.", "preferredTerm": "Planned Trial Duration", "submissionValue": "Planned Trial Duration", "synonyms": ["Planned Trial Duration"]}, {"conceptId": "C139168", "definition": "The name of the entity that is considered the primary sponsor for the trial or study. (NCI)", "preferredTerm": "Primary Study Sponsor Name", "submissionValue": "Primary Sponsor Name"}, {"conceptId": "C139169", "definition": "The name of the entity that is considered the secondary sponsor for the trial or study. (NCI)", "preferredTerm": "Secondary Study Sponsor Name", "submissionValue": "Secondary Sponsor Name"}, {"conceptId": "C139167", "definition": "The major organizations providing monetary or material support for the conduct of the trial, including, but not limited to, funding, design, implementation, data analysis and reporting. (EudraCT)", "preferredTerm": "Source of Monetary or Material Support for Study", "submissionValue": "Source of Monetary or Material Support for Study"}, {"conceptId": "C139172", "definition": "The total number of planned participants in a study or trial.", "preferredTerm": "Target Sample Size", "submissionValue": "Target Sample Size"}, {"conceptId": "C101302", "definition": "A categorization of a disease, disorder, or other condition based on common characteristics and often associated with a medical specialty focusing on research and development of specific therapeutic interventions for the purpose of treatment and prevention.", "preferredTerm": "Therapeutic Area", "submissionValue": "Therapeutic Area", "synonyms": ["Therapeutic Area"]}, {"conceptId": "C15787", "definition": "The detailed planning of a study of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. (NCI)", "preferredTerm": "Clinical Trials Design", "submissionValue": "Trial Design"}, {"conceptId": "C112038", "definition": "The textual representation of the condition, disease or disorder that the clinical trial is intended to investigate or address.", "preferredTerm": "Trial Indication", "submissionValue": "Trial Disease/Condition Indication", "synonyms": ["Trial Disease/Condition Indication", "Trial Disease/Condition Indication Description"]}, {"conceptId": "C49652", "definition": "The planned purpose of the therapy, device, or agent under study in the clinical trial.", "preferredTerm": "Clinical Study by Intent", "submissionValue": "Trial Intent", "synonyms": ["Trial Intent Type"]}, {"conceptId": "C48281", "definition": "A step in the clinical research and development of a therapy from initial clinical trials to post-approval studies. NOTE: Clinical trials are generally categorized into four (sometimes five) phases. A therapeutic intervention may be evaluated in two or more phases simultaneously in different trials, and some trials may overlap two different phases. [21 CFR section 312.21; After ICH Topic E8 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS, CPMP/ICH/291/95 March 1998]", "preferredTerm": "Trial Phase", "submissionValue": "Trial Phase", "synonyms": ["Trial Phase", "Trial Phase Classification"]}, {"conceptId": "C85826", "definition": "A principle objective of the study.", "preferredTerm": "Trial Primary Objective", "submissionValue": "Trial Primary Objective", "synonyms": ["Study Primary Objective", "Trial Primary Objective"]}, {"conceptId": "C139166", "definition": "An indication as to whether the clinical trial has been registered with a trial registry system.", "preferredTerm": "Trial Registration Indicator", "submissionValue": "Trial Registration Indicator"}, {"conceptId": "C85827", "definition": "An auxiliary objective of the study.", "preferredTerm": "Trial Secondary Objective", "submissionValue": "Trial Secondary Objective", "synonyms": ["Study Secondary Objective", "Trial Secondary Objective"]}, {"conceptId": "C85838", "definition": "Any healthcare organization, institution, facility or provider directly involved in conducting or facilitating a particular clinical trial. (NCI)", "preferredTerm": "Clinical Trial Site", "submissionValue": "Trial Site", "synonyms": ["Investigative Site", "Investigator Site"]}, {"conceptId": "C49660", "definition": "The nature of the interventional study for which information is being collected.", "preferredTerm": "Trial Type", "submissionValue": "Trial Type", "synonyms": ["Trial Scope", "Trial Type"]}]}